IBTC
Monochrome Bitcoin ETF
🇦🇺 ASX
👑 Overview
📈 Performance
📙 Holdings
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
16
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Monochrome Bitcoin ETF
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →📙 Top Holdings
Show moreTop holdings information is not yet available for this fund. For more information please visit the fund manager's website.
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$15.68
💰 Price To Earnings Ratio
0.00
💰 Price To Book Ratio
0.00
💰 Leveraged
No
💰 Inverse
No
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in IBTC
16
📊 Total Capital Earnings
$58K
🔃 Average investment frequency
20 weeks
💵 Average investment amount
$4,201
⏰ Last time a customer invested in IBTC
1 day
IBTC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
10%
50k - 100k
35%
Less than 50k
50%
👶 Age of investors
18 - 25
26 - 34
38%
35 - 90
56%
🙋 Legal gender of investors
Female
63%
Male
38%
Pearlers who invest in IBTC also invest in...
IVV
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
20.94%
📊 Share price
$63.52 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.66%
📊 Share price
$103.19 AUD
🇦🇺 AUSTRALIA
⛳️ DIVERSIFIED
🧱 MATERIALS
💸 FINANCIALS
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
4.03%
📊 Share price
$69.71 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
4.17%
📊 Share price
$139.14 AUD
⛳️ DIVERSIFIED
💸 FINANCIALS
🇦🇺 AUSTRALIA
Want more shares? Try these...
IBUY.AX was created on 2022-02-14 by BetaShares. The fund's investment portfolio concentrates primarily on consumer discretionary equity. IBUY.AX aims to track the performance of an Index (before fees and expenses) that provides exposure to a portfolio of the worlds leading online retailers.
📊 Share price
$15.54 AUD
🛍️ CONSUMER
🌏 GLOBAL
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The firm uses bio-safe magnetic nanoparticles to detect cancer and other diseases. Its principal activity consists of nanotechnology, biotechnology, cancer diagnostics and medical imaging using magnetic resonance. The firm operates through Research and Development segment. The company is advancing clinical development of its MagSense platform technology to revolutionize cancer diagnosis, introducing molecular imaging to Magnetic resonance imaging (MRI). The Company’s lead program has demonstrated its technology embodied in MagSense HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Its MagSense pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.
🙌 Performance (5Yr p.a)
8.24%
📊 Share price
$0.02 AUD
🩺 HEALTH CARE
📈 HIGH PRICE GROWTH
